Perrigo (PRGO) to Release Earnings on Wednesday

Perrigo (NYSE:PRGO) is anticipated to issue its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.75 per share and revenue of $1.1010 billion for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:30 AM ET.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, August 6th. The company reported $0.57 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.02). The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The firm’s revenue was down .9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.53 earnings per share. On average, analysts expect Perrigo to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Perrigo Trading Up 0.3%

Shares of PRGO opened at $20.71 on Monday. Perrigo has a one year low of $20.40 and a one year high of $30.93. The stock has a 50-day moving average price of $22.01 and a 200 day moving average price of $24.69. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.24 and a current ratio of 2.32. The company has a market capitalization of $2.85 billion, a P/E ratio of -35.71 and a beta of 0.43.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 16th. Shareholders of record on Friday, November 28th will be given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 5.6%. The ex-dividend date of this dividend is Friday, November 28th. Perrigo’s dividend payout ratio is presently -200.00%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Jefferies Financial Group decreased their price target on shares of Perrigo from $27.00 to $23.00 and set a “hold” rating for the company in a research report on Monday, October 27th. JPMorgan Chase & Co. reduced their price objective on shares of Perrigo from $38.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Canaccord Genuity Group dropped their target price on shares of Perrigo from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Wall Street Zen upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a research note on Sunday, October 26th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Perrigo in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $31.25.

Insider Activity

In other Perrigo news, EVP Abigail Lennox purchased 1,255 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were bought at an average price of $22.41 per share, with a total value of $28,124.55. Following the completion of the acquisition, the executive vice president owned 1,255 shares in the company, valued at approximately $28,124.55. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Eduardo Guarita Bezerra acquired 3,000 shares of Perrigo stock in a transaction dated Monday, August 18th. The shares were acquired at an average price of $22.74 per share, with a total value of $68,220.00. Following the completion of the transaction, the chief financial officer owned 48,949 shares of the company’s stock, valued at approximately $1,113,100.26. This trade represents a 6.53% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 10,118 shares of company stock valued at $232,699. Company insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. State Street Corp grew its position in Perrigo by 9.5% in the 2nd quarter. State Street Corp now owns 7,340,323 shares of the company’s stock valued at $196,134,000 after buying an additional 637,678 shares in the last quarter. Ion Asset Management Ltd. boosted its holdings in shares of Perrigo by 34.7% in the second quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock valued at $102,007,000 after acquiring an additional 983,727 shares in the last quarter. BW Gestao de Investimentos Ltda. increased its stake in shares of Perrigo by 13.2% during the second quarter. BW Gestao de Investimentos Ltda. now owns 1,469,524 shares of the company’s stock valued at $39,266,000 after acquiring an additional 171,080 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Perrigo by 52.5% during the second quarter. Ameriprise Financial Inc. now owns 1,308,334 shares of the company’s stock valued at $34,959,000 after acquiring an additional 450,247 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in Perrigo by 126.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after purchasing an additional 647,982 shares in the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.